Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01377909 · ClinicalTrials.gov registry record · Phase 1
HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity
A Phase 1 study, sponsored by Bader, Ted, M.D..
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01377909 is a Phase 1 study that was terminated before completion, run by Bader, Ted, M.D.. The registered enrollment target is 20 participants.
The verdict
NCT01377909, a Phase 1 study, was terminated before completion, sponsored by Bader, Ted, M.D..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Objective: The goal is to improve peginterferon sensitivity in previous poor responders. "Sensitivity" here means the host's ability to kill more HCV. Design: Twenty poor responders to prior PIFN/RBV will be given 48 weeks of statin monotherapy. Veterans and civilians between the ages of 18 and 70 are eligible.
Interventions
- DRUG statin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01377909
The ClinicalTrials.gov registry entry for NCT01377909 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bader, Ted, M.D., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which statin is the first listed.
NCT01377909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01377909 about?
NCT01377909 is a clinical study titled "HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity". Objective: The goal is to improve peginterferon sensitivity in previous poor responders. "Sensitivity" here means the host's ability to kill more HCV. Design: Twenty poor responders to prior PIFN/RBV will be given 48 weeks of statin monotherapy. Veterans and civilians between the ages of 18 and 70 ...
What is the current status of trial NCT01377909?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2012-03. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01377909?
The interventions under investigation include: statin (DRUG).
Who is sponsoring clinical trial NCT01377909?
This trial is sponsored by Bader, Ted, M.D., which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.